Zai Lab presents positive outcomes from KarXT Phase III trial for schizophrenia

By Yahoo! Finance | Oct 30, 2024 at 06:35 AM EST

Zai Lab's Phase III trial of KarXT for schizophrenia in China showed positive outcomes, meeting primary and secondary endpoints. The trial demonstrated the potential of KarXT as a new treatment option. Zai Lab plans to submit an NDA to NMPA by early 2025.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.